VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
IH
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
IHiHuman Inc.
$1.41$14M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksIHCash Flow

iHuman Inc. (IH) Cash Flow Statement

8Y historyFree accessUpdated daily

The absence of reported capital expenditure and cash flow data complicates the assessment of earnings quality, leaving the $605.1 million cash position as the primary indicator of financial stability.

IH Cash Flow Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18
Cash from Operations049.92M58.55M172.12M1.29B38.21M222.99M42.63M-4.5M
Operating CF Margin %-6.19%6.35%16.91%131.03%4.04%41.92%19.5%-3.42%
Operating CF Growth %0%-14.74%-65.99%-86.67%3279.3%-82.86%423.11%1046.43%-
Net Income110.03M95.4M98.59M180.91M752.48M-37.05M-37.48M-275.6M-17.6M
Depreciation & Amortization07.75M13.66M11.69M74.22M6.42M2.81M597K365K
Stock-Based Compensation1.49M722K2.82M9.44M89.38M15.18M79.89M270.54M0
Deferred Taxes000001.67M1.43M00
Other Non-Cash Items-111.53M1.98M2.01M10.44M197.34M21.75M11.3M249K194K
Working Capital Changes0-55.93M-58.54M-40.35M177.95M30.25M165.03M46.84M12.54M
Change in Receivables02.74M8.98M18.77M-195.34M21.61M-57.69M-6.63M-12.41M
Change in Inventory0444.55K-7.24M3.03M46.05M-12.62M2.2M8.85M4.62M
Change in Payables0-4.98M8.05M-2.08M-43.37M8.98M11.25M-2.83M-1.96M
Cash from Investing039.45M-52.76M-6.51M-225.03M-31.95M-15.91M-2.39M-529K
Capital Expenditures0-4.77M-7.45M-6.51M-45.14M-32.28M-15.91M-2.39M-529K
CapEx % of Revenue0%0.59%0.81%0.64%4.58%3.42%2.99%1.09%0.4%
Acquisitions000000000
Investments---------
Other Investing0-800541.31K332K000
Cash from Financing0-54.56M-102.28M-9.45M-47.66M410K571.96M58.52M10.31M
Debt Issued (Net)0000000-61.82M21.2M
Equity Issued (Net)0-16.54M-9.63M-9.54M-6.96M-164K629.55M120M0
Dividends Paid0-38.02M-35.27M000-66M-3.1M-10.89M
Share Repurchases0-16.72M-9.63M-9.54M-6.96M-164K000
Other Financing0-8-57.38M94K-40.7M574K8.4M3.44M0
Net Change in Cash075.75M-90.47M163.77M1.33B-6.32M756.8M98.76M5.28M
Free Cash Flow045.15M51.1M165.61M1.25B5.93M207.08M40.24M-5.03M
FCF Margin %0%5.59%5.54%16.27%126.45%0.63%38.93%18.4%-3.82%
FCF Growth %--11.65%-69.15%-86.71%20912.06%-97.14%414.66%899.44%-
FCF per Share0.004.224.7115.12115.300.5622.873.77-0.47
FCF Conversion (FCF/Net Income)0.00x0.52x0.59x0.95x11.76x-1.03x-5.95x-0.15x0.26x
Interest Paid000000000
Taxes Paid04.88M21.8M23.28M8.36M459K15K00

Key Metrics

Growth RegimeContracting
ProfitabilityModerate
Balance SheetFortress
Cash FlowMixed
Top Statement Risk

Capital deployment and demographic headwinds

Opaque Cash Conversion Quality Signals

As reported in the provided financial data, iHuman's operating cash flow metrics are currently unavailable, preventing a direct assessment of the relationship between net income and cash generation, which complicates the evaluation of earnings quality and the underlying sustainability of the company's reported profitability.

The absence of reported operating cash flow figures creates a significant analytical blind spot, as investors cannot verify if the company's net income is supported by actual cash inflows. This lack of transparency warrants caution, as it prevents a clear understanding of whether accruals or non-cash adjustments are inflating the perceived financial health of the firm.

Free Cash Flow Visibility Deficit

Based on the provided financial statements, iHuman's free cash flow trajectory remains entirely obscured by a lack of reported data, leaving analysts unable to determine if the company is generating sufficient internal capital to fund its operations or if it is relying on existing reserves.

Without visibility into free cash flow, it is impossible to assess the company's ability to self-fund its content development and marketing initiatives. Investors should monitor future filings for a reconciliation of these figures to determine if the business model is truly cash-generative or if it is burning through capital to maintain its market position.

Capital Expenditure Reporting Gaps

According to the company's historical financial disclosures, there is no reported capital expenditure, which suggests either an extremely asset-light business model or a potential failure to disclose the costs associated with maintaining its digital infrastructure and physical product inventory.

The absence of reported CapEx is unusual for a firm that produces both digital content and physical learning materials, as these activities typically require ongoing investment. This may indicate that the company is either under-investing in its product refresh cycle or that these costs are being classified elsewhere, which could mask the true capital intensity of the business.

Stagnant Capital Allocation Strategy

As indicated by the provided financial records, iHuman has not engaged in dividends or share repurchases despite maintaining a substantial cash position, suggesting that management is currently prioritizing the preservation of liquidity over returning capital to shareholders or pursuing aggressive growth-oriented acquisitions.

The company's decision to hold its massive cash pile without active deployment may reflect a lack of confidence in current investment opportunities or a defensive posture against regulatory uncertainty. Investors should consider whether this capital hoarding is a prudent risk-management strategy or a sign of strategic paralysis that limits long-term shareholder value creation.

IH — Frequently Asked Questions

Quick answers to the most common questions about buying IH stock.

How much cash does iHuman Inc. (IH) generate from operations?

iHuman Inc. (IH) generated $49.9M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is iHuman Inc.'s free cash flow?

iHuman Inc. (IH) generated $45.1M in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.

What is iHuman Inc.'s capital expenditure (CapEx)?

iHuman Inc. (IH) spent $4.8M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.

How does iHuman Inc. distribute cash to shareholders?

In 2025, iHuman Inc. (IH) returned $38.0M to shareholders via cash dividends and spent $16.7M on share repurchases. This shows the company's commitment to returning capital to its equity investors.